Novo Nordisk CEO Lars Fruergaard Jorgensen says starter doses of the company’s weight loss medications will “be lowered somewhat” through the end of the year as the company plans to be “gradually expanding and bringing more and more product to the US.” He speaks on "Bloomberg The Open."